Email this article Сombined treatment of squamous-cell anal cancer
- Authors: Kim D.F.1, Nikolayev A.V.1, Barsukov Y.A.1, Tkachev S.I.1, Gordeyev S.S.2
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- Issue: Vol 1, No 4 (2012)
- Pages: 9-14
- Section: IN FOCUS
- Published: 28.02.2015
- URL: https://onco-surgery.info/jour/article/view/59
- DOI: https://doi.org/10.17650/2220-3478-2012-0-4-9-14
- ID: 59
Cite item
Full Text
Abstract
Since 1974 chemoradiation scheme proposed by Nigro remains the standard of care for squamous-cell anal cancer in most countries. Improvement of treatment results can be achieved by developing new treatment schemes including different radio- and chemosensitizers.
Methods. Results of treatment of 157 T1–4N0–2M0 squamous-cell anal cancer patients, which underwent treatment during 1990–2012 were analyzed. Patients were divided into 3 groups: group A received hyperfractionated radiotherapy (RT) single dose 1.2 Gy bid, total dose 40–44 Gy with 3–5 sessions of local hyperthermia (HT) during treatment; group B had similar RT + HT scheme with addition of chemotherapy (CT) with cisplatin 20 mg/m2 in days 1, 3 weeks 1–4 and bleomycin 15 mg in days 2, 4 weeks 1–4; group C had RT with single dose 2 Gy, same total dose, HT and CT as in group B and additionally received metronidazole 10 g/m2 per rectum in a polymeric composition. Two weeks after 1st treatment stage a second course of RT was carried out 20–24 Gy in 2 Gy fractions in all patient groups.
Results. Sphincter-sparing treatment was carried out in 11 (50 %), 71 (80.68 %) and 44 (93.62 %) in groups A, B and C accordingly. Three year overall survival (OS) was 60.0; 82.4; 96.4 %; 3-year disease-free survival (DFS) 36.6; 69.8 and 76.3 % accordingly.
Conclusions. In our study combined treatment using radiosensitization allow to improve sphincter preservation rate to 93 %, improve OS and DFS for squamous-cell anal cancer patients.
About the authors
D. F. Kim
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: kdf1976@rambler.ru
Russian Federation
A. V. Nikolayev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
Yu. A. Barsukov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
S. I. Tkachev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Email: fake@neicon.ru
Russian Federation
S. S. Gordeyev
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Email: fake@neicon.ru
Department of Oncology, Faculty of Therapeutics Russian Federation
References
Supplementary files
